<DOC>
	<DOC>NCT02235259</DOC>
	<brief_summary>The objective of this study is to assess the safety and efficacy of XG-104 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye after a 4 week Three Times a Day (TID) treatment period</brief_summary>
	<brief_title>Efficacy and Safety of XG-104 for the Treatment of Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Be at least 18 years of age Provide written informed consent Have a subject reported history of dry eye Have a history of use or desire to use eye drops Have any clinically significant eye findings that require therapeutic treatment, and/or in the opinion of the Investigator may interfere with study parameters; Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study; Have previously had laserassisted in situ keratomileusis (LASIK) surgery within the last 12 months; Have used RestasisÂ® within 30 days of Visit 1; Have any planned ocular and/or lid surgeries over the study period; Be a woman who is pregnant, nursing or planning a pregnancy; Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 4 (or early termination visit) if of childbearing potential. Have a known allergy and/or sensitivity to the study drug or its components Have a condition or be in a situation which the Investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study; Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1; Be unable or unwilling to follow instructions, including participation in all study assessments and visits</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>